|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2.
|
Pignata S, Cannella L, Leopardo D, Pisano
C, Bruni GS and Facchini G: Chemotherapy in epithelial ovarian
cancer. Cancer Lett. 303:73–83. 2011. View Article : Google Scholar
|
|
3.
|
Gonzalez-Martin AJ: Medical treatment of
epithelial ovarian cancer. Expert Rev Anticancer Ther. 4:1125–1143.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Matsuo K, Lin YG, Roman LD and Sood AK:
Overcoming platinum resistance in ovarian carcinoma. Expert Opin
Investig Drugs. 19:1339–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Lanier LL: NK cell recognition. Annu Rev
Immunol. 23:225–274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: from immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Orr MT and Lanier LL: Natural killer cell
education and tolerance. Cell. 142:847–856. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Smyth MJ, Dunn GP and Schreiber RD: Cancer
immunosurveillance and immunoediting: the roles of immunity in
suppressing tumor development and shaping tumor immunogenicity. Adv
Immunol. 90:1–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Altomare DA, Wang HQ, Skele KL, et al: AKT
and mTOR phosphorylation is frequently detected in ovarian cancer
and can be targeted to disrupt ovarian tumor cell growth. Oncogene.
23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Cheng JQ, Lindsley CW, Cheng GZ, Yang H
and Nicosia SV: The Akt/PKB pathway: molecular target for cancer
drug discovery. Oncogene. 24:7482–7492. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Steelman LS, Chappell WH, Abrams SL, et
al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in
controlling growth and sensitivity to therapy-implications for
cancer and aging. Aging. 3:192–222. 2011.PubMed/NCBI
|
|
12.
|
Levine DA, Bogomolniy F, Yee CJ, et al:
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Clin Cancer Res. 11:2875–2878. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Benedetti V, Perego P, Luca Beretta G, et
al: Modulation of survival pathways in ovarian carcinoma cell lines
resistant to platinum compounds. Mol Cancer Ther. 7:679–687. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Engel JB, Schonhals T, Hausler S, et al:
Induction of programmed cell death by inhibition of AKT with the
alkylphosphocholine perifosine in in vitro models of platinum
sensitive and resistant ovarian cancers. Arch Gynecol Obstet.
283:603–610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Santiskulvong C, Konecny GE, Fekete M, et
al: Dual targeting of phosphoinositide 3-kinase and mammalian
target of rapamycin using NVP-BEZ235 as a novel therapeutic
approach in human ovarian carcinoma. Clin Cancer Res. 17:2373–2384.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Westfall SD and Skinner MK: Inhibition of
phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to
carboplatin and allows adjunct chemotherapy treatment. Mol Cancer
Ther. 4:1764–1771. 2005. View Article : Google Scholar
|
|
17.
|
Hahne JC, Honig A, Meyer SR, et al:
Downregulation of AKT reverses platinum resistance of human ovarian
cancers in vitro. Oncol Rep. 28:2023–2028. 2012.PubMed/NCBI
|
|
18.
|
Behrens BC, Hamilton TC, Masuda H, et al:
Characterization of a cis-diamminedichloroplatinum(II)-resistant
human ovarian cancer cell line and its use in evaluation of
platinum analogues. Cancer Res. 47:414–418. 1987.PubMed/NCBI
|
|
19.
|
Valiante NM, Rengaraju M and Trinchieri G:
Role of the production of natural killer cell stimulatory factor
(NKSF/IL-12) in the ability of B cell lines to stimulate T and NK
cell proliferation. Cell Immunol. 145:187–198. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Sheehy ME, McDermott AB, Furlan SN,
Klenerman P and Nixon DF: A novel technique for the fluorometric
assessment of T lymphocytic antigen specific lysis. J Immunol
Methods. 249:99–110. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Jesnowski R, Backhaus C, Ringel J and Lohr
M: Ribosomal highly basic 23-kDa protein as a reliable standard for
gene expression analysis. Pancreatology. 2:421–424. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Caligiuri MA: Human natural killer cells.
Blood. 112:461–469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Vivier E, Raulet DH, Moretta A, et al:
Innate or adaptive immunity? The example of natural killer cells.
Science. 331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Lanier LL: Up on the tightrope: natural
killer cell activation and inhibition. Nat Immunol. 9:495–502.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Moretta L, Biassoni R, Bottino C, Mingari
MC and Moretta A: Human NK-cell receptors. Immunol Today.
21:420–422. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Bellucci R, Nguyen HN, Martin A, et al:
Tyrosine kinase pathways modulate tumor susceptibility to natural
killer cells. J Clin Invest. 122:2369–2383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Boutet P, Agüera-Gonza’lez S, Atkinson S,
et al: Cutting edge: the metalloproteinase ADAM17/TNF-α-converting
enzyme regulates proteolytic shedding of the MHC class I-related
chain B protein. J Immunol. 182:49–53. 2009.PubMed/NCBI
|
|
28.
|
Waldhauer I, Goehlsdorf D, Gieseke F, et
al: Tumor-associated MICA is shed by ADAM proteases. Cancer Res.
68:6368–6376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Okita R, Mougiakakos D, Ando T, et al:
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC
class I chain-related molecule A and B expression in human breast
cancer cell lines. J Immunol. 188:2136–2145. 2012. View Article : Google Scholar : PubMed/NCBI
|
